Use of aspirin in reduction of mortality of COVID-19 patients: A metanalysis

Link to article at PubMed

Int J Clin Pract. 2021 Jun 12:e14515. doi: 10.1111/ijcp.14515. Online ahead of print.


COVID-19 infection affecting every one of us from the last year and continue to affecting. Emerging reports have indicated thrombo-embolism in serious cases of COVID-19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID-19 patients using Rev Man 5. A total of 10 studies containing 56, 696 COVID-19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle-Ottawa Scale. The fixed-effect model was used to calculate the odds ratio with 95% C.I. The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser like hood of having a death in COVID-19 patients in aspirin group as compared to non-aspirin group. However, no effect 0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.

PMID:34118111 | DOI:10.1111/ijcp.14515

Leave a Reply

Your email address will not be published.